Ali G. Turhan

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 409 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

Xiaoyan Jiang, Yun Zhao, Clayton A. Smith et al. · Leukemia · 2007 · 358 citations

Medicine, Hematology, Oncology +12

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects

Christophe Borg, Magali Terme, Cédric Menard et al. · Journal of Clinical Investigation · 2004 · 287 citations · Full text

Medicine, Immunology, Oncology +17

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

Jean‐Claude Chomel, Marie‐Laure Bonnet, Nathalie Sorel et al. · Blood · 2011 · 196 citations · Full text

Medicine, Hematology, Oncology +16

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

Chris T. Williamson, Huong Muzik, Ali G. Turhan et al. · Molecular Cancer Therapeutics · 2010 · 191 citations · Full text

Medicine, Molecular Biology, Oncology +17